Each report covers a single therapy in a single indication, published within days of approval. A free two page executive summary is available for every published report.
Full reports are 25 pages with internal team sharing included. Reports marked available now download instantly after payment; others are written on order and delivered within 5 business days.
Approved on 9 October 2026, Teva's Weltruza is the first once monthly subcutaneous olanzapine and the first olanzapine long acting injectable without post injection monitoring. The report sizes its share of the US long acting antipsychotic market against Invega, Abilify Maintena and Teva's own Uzedy.
On 23 October 2026 the FDA made Awiqli the first once weekly insulin approved for children 10 years and older, a month after Lilly's Onswik was approved for adults only. The report sizes the US weekly insulin opportunity across adults and children and what the children's label is really worth.
AbbVie's lutikizumab, the first antibody to block both IL-1 alpha and IL-1 beta, met its Phase III goal in hidradenitis suppurativa on 22 October 2026 with a clean safety profile, but by a modest margin. The report assesses its chances against Humira, Cosentyx and Bimzelx ahead of a planned 2027 filing.
FDA approval on 9 October 2026 made Hovilpri the first helicase primase inhibitor, an oral option for immunocompromised adults whose herpes lesions do not respond to standard antivirals. The report sizes a small but high value niche now served by toxic intravenous drugs.
Lilly's Foundayo is the first GLP-1 pill that can be taken at any time without food or water rules, approved by the FDA for obesity on 1 April 2026 and backed by the EU committee on 16 October 2026. The report assesses how far an easy to take, easy to make pill can widen the market against the Wegovy pill and the injectables.
FDA approval on 26 August 2026 made Revolution Medicines' Rasonque the first RAS(ON) inhibitor, after it roughly doubled survival over chemotherapy in previously treated metastatic pancreatic cancer. The report assesses the second line launch, the first line opportunity, and the toxicity and pricing questions that will shape uptake.
FDA approval on 20 October 2026 made GSK's Hibsago the first antisense therapy for chronic hepatitis B and the first drug to deliver functional cure in a meaningful share of patients. The report assesses how far a narrow label, a boxed warning and specialist monitoring will limit a fixed 24 week course.
FDA approval on 15 October 2026 made Enspryng the first thyroid eye disease therapy that patients can inject themselves at home. The report assesses whether convenience can win share from an established intravenous market leader, despite a missed primary endpoint in one pivotal trial.
Coverage is selected from recent FDA and EMA approvals and Phase III readouts with meaningful commercial questions. Reports are added here as they enter production.
Download any free executive summary to be notified the day the next report is published.
We accept a limited number of custom reports, using the same structure and methodology as our published reports. Tell us the product, the indication and your deadline.